IL15 and cancer: Cancers with decreased IL-15 expression correlate with decreased patient survival (47), which led to the development of IL-15 superagonists (48–50) and NK cell modifications that can overcome TGF-β-mediated inhibition of the IL-15 pathway (51, 52).